

1. (Original) A glutamic acid receptor protein having the following properties:
 - (A) it has a transmembrane domain and an intracellular domain common to those of type 4 metabotropic glutamic acid receptor protein, and
 - (B) It has an extracellular domain by about 316 or 327 amino acid residues shorter than that of the type 4 metabotropic glutamic acid receptor protein.
2. (Original) The glutamic acid receptor protein according to claim 1, wherein the protein is expressed in rat small intestine and large intestine.
3. (Original) The glutamic acid receptor protein according to claim 1, wherein the protein comprises the amino acid sequence shown in SEQ ID NO: 7 or the amino acid sequence consisting of amino acids numbers 12 to 584 in the amino acid sequence shown in SEQ ID NO: 7.
4. (Currently amended) A DNA which encodes a glutamic acid receptor protein according to ~~any one of claims 1 to 3~~ claim 1 and does not

express type 4 metabotropic glutamic acid receptor protein.

5. (Currently amended) A cell harboring a DNA which encodes the glutamic acid receptor protein according to ~~any one of claims 1 to 3~~ claim 1 in an expressible form.
6. (Currently amended) A method of producing glutamic acid receptor protein or a cell harboring the glutamic acid receptor protein, comprising cultivating a cell harboring a DNA which encodes the glutamic acid receptor protein according to ~~any one of claims 1 to 3~~ claim 1 in an expressible form in a medium to produce the glutamic acid receptor protein.
7. (Currently amended) A method of screening an agonist, an antagonist, or an allosteric modulator of glutaminc acid, comprising the steps of reacting the glutamic acid receptor protein according to ~~any one of claims 1 to 3~~ claim 1 with a substance that binds

to the protein in the presence of a test substance, and detecting inhibition or promotion of the reaction.

8. (Currently amended) A method of screening an agonist of glutamic acid comprising the steps of reacting a glutamic acid receptor protein according to ~~any one of claims 1 to 3~~ claim 1 and a test substance, and detecting the reaction.
9. (Currently amended) A method according to claim 7, wherein the cell ~~according to claim 6~~ harboring a DNA which encodes the glutamic acid receptor protein or a membrane fraction prepared from the cell is used as the glutamic acid receptor protein.
10. (Original) A method according to claim 9, wherein the inhibition or promotion of the binding is detected by a second messenger generated by the glutamic acid receptor protein.
11. (Currently amended) A method according to claim 8, wherein

the cell according to claim 5 harboring
a DNA which encodes the glutamic acid
receptor protein or a membrane fraction
prepared from the cell is used as the
glutamic acid receptor protein.

12. (Original) A method according to claim 11, wherein inhibition or promotion of the binding is detected by a second messenger generated by the glutamic acid receptor protein.
13. (Currently amended) An antibody that specifically binds to the glutamic acid receptor protein according to ~~any one of claims 1 to 3~~
claim 1.
14. (Currently amended) A method of producing a drug for modulating a second messenger generated by binding glutamic acid to a glutamic acid receptor, comprising the steps of: reacting the glutamic acid receptor protein according to ~~any one of claims 1 to 3~~
claim 1 with a substance that binds to the protein in the presence of a test

substance and detecting inhibition or promotion of the reaction to screen an agonist, an antagonist, or an allosteric modulator of glutamic acid; and preparing a pharmaceutical composition containing the agonist, antagonist, or allosteric modulator of glutamic acid obtained in the reacting step as an active ingredient.

15. (Currently amended) A method of producing a drug for modulating a second messenger generated by binding glutamic acid to a glutamic acid receptor, comprising the steps of: reacting the glutamic acid receptor protein according to ~~any one of claims 1 to 3~~ claim 1 with a test substance and detecting the reaction to screen an agonist of glutamic acid; and preparing a pharmaceutical composition containing the agonist of glutamic acid obtained in the reacting step as an active ingredient.